The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy

Abstract

Background:To observe the effect of alogliptin combined with metformin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy (500 mg, bid po, for at least 3 months), and evaluate its efficacy and safety.Methods:After a 2-week screening period, adult patients (aged 36–72 years) entered a 4-week run-in/stabilization period. Then, patients were randomly assigned to either the intervention group (n = 55) or the control group (n = 50) for 26 weeks. The patients in the control group were given metformin (1000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po). All the patients received counseling about diet and exercise from a nutritionist during run-in and treatment periods.The primary endpoints were the between-group differences in the changes in pulmonary function parameters (vital capacity [VC]%, forced vital capacity [FVC]%, forced expiratory volume in 1 second (FEV1)%, peak expiratory force [PEF]%, maximal voluntary ventilation [MVV]%, total lung capacity [TLC%], forced expiratory volume in 1 second/forced vital capacity [FEV1/FVC%], diffusing capacity for carbon monoxide of lung [DLCO]%, and diffusing capacity for carbon monoxide of lung/unit volume [DLCO/VA%]) between pretherapy and posttreatment. The secondary endpoints were changes from baseline to week 26 in glycosylated hemoglobinA1c (HbA1c), FPG, 2hPG, homeostasis model assessment insulin resistance (HOMA-IR), waist circumference (WC), and BMI. The tertiary endpoints were the changes from baseline to week 26 in blood-fat (total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], and triglycerides [TG]). The quartus endpoints were the changes from baseline to week 26 in systolic blood pressure (SBP) and diastolic blood pressure (DBP). The 5th endpoints were the changes from baseline to week 26 in oxidative/antioxidative parameters (reactive oxygen species [ROS], malondialdehyde [MDA], superioxide dismutase [SOD], and glutathione peroxidase [GSH-Px]). In addition, safety endpoints were assessed (AEs, clinical laboratory tests, vital signs, and electrocardiographic readings).Results:Eighty-one patients completed our clinical trial: intervention group (n = 44) and control group (n = 37). At week 26, pulmonary function parameters (VC%, FVC%, FEV1%, PEF%, MVV%, TLC%, FEV1/FVC%, DLCO%, and DLCO/VA%) had increased significantly from pretherapy values in both groups (P < 0.05), and the pulmonary function tests were significantly greater (P < 0.05) in intervention group than in controls posttherapy. Pulmonary function (FVC%, FEV1%, PEF%, TLC%, FEV1/FVC%, DLCO%, and DLCO/VA%) was lower in the group with HbA1c levels ≥8.0 at 26 weeks, but VC%, FEV1%, MVV%, and TLC% were not significantly lower (P > 0.05). Pulmonary function parameters were positively correlated with GSH-Px and SOD and negatively correlated with ROS and MDA. Mean declines in HbA1c, FPG, 2hPG, HOMA-IR, a...

Pulmonary Function and Retrobulbar Hemodynamics in Subjects With Type 2 Diabetes Mellitus

“…Pulmonary function parameters are positively correlated with glutathione peroxidase and superoxide dismutase activity and negatively correlated with reactive oxygen species and malondialdehyde levels. 19 Systemic inflammation is another concern of diabetic patients, because oxidative stress-induced systemic inflammation is associated with endothelial dysfunction in diabetic patients. [20][21][22] Additionally, insulin resistance could alter lung volume and mechanical function via mediators such as leptin 18 as well as independently lead to air flow obstruction in a manner similar to that in which peripheral airway inflammation causes air flow obstruction in asthma.…”

Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: An Overview

“…We need to know more about the effects of oral hypoglycaemic agents on the lungs. This holds true for metformin, pioglitazone [48,49], DPP-4 inhibitors [65,66] and SGLT2 inhibitors. GLP-1RAs also need to be examined in this context, in view of their promising preliminary results regarding improved lung function [68].…”

“…No data exist for the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors (e. g. linagliptin, sitagliptin, alogliptin, vildagliptin and saxagliptin) on COPD outcomes. However, sitagliptin was shown to reduce airway remodelling and inflammation in an experimental model of chronic asthma [65] and alogliptin was reported to improve lung function in obese subjects with T2DM [66].…”

Circadian Clock and Sirtuins in Diabetic Lung: A Mechanistic Perspective

“…The reduction in DLCO in diabetic patients is parallel to the severity of retinopathy and nephropathy (15). Moreover, glycemic control increases DLCO (28). Pulmonary mechanical function is reflected by several parameters, including forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and total lung capacity (TLC).…”